Enter your email address below and we will send you the reset instructions, If the address matches an existing account you will receive an email with instructions to reset your password, Enter your email address below and we will send you your username, If the address matches an existing account you will receive an email with instructions to retrieve your username. 47, No. The purpose of this study is to determine whether memantine is safe and effective when used as an augmentation to standard treatment for Obsessive-Compulsive Disorder (OCD). Secondary outcomes of interest included changes in comorbid depression severity as measured by the BDI, psy-chosocial functioning changes as measured by the WSA scale, At study end, 6 subjects (42.9%) were responders, and response was achieved by EOW4. Memantine as an Augmenting Agent for Severe Pediatric OCD TO THE EDITOR: The present case study is a follow-up to a previous case report (1), published in the Journal, on effective augmentation of the glutamatergic agent memantine to treat severe adult obsessive compulsive disorder (OCD). It helps with anxiety and oversensitivity issues, especially in people with autism, OCD, schizophrenia. Unfortunately, a controlled study of memantine in depression from the National Institute of Mental Health did not show benefit. 2009 Nov;70(11):1530-5. doi: 10.4088/JCP.08m04605. 6 comments. She developed compulsive checking behavior to decrease the associated anxiety. Another drug, the N-methyl-d-aspartate antagonist memantine, has recently been tested in the treatment of OCD. 19, No. Storch , EA , Merlo , LJ , Bengtson , M et al ( 2007 ) D-cycloserine does not enhance exposure-response prevention therapy in obsessive–compulsive disorder . According to some studies, memantine has shown some potential when used in addition to first-line treatments for OCD. However, because this meta-analysis included only three small-sized RCTs (number of patients: 32–42), future studies using a larger sample size should be conducted to obtain more robust results. Sort by. In this open-label augmentation trial of memantine in treatment-resistant OCD, almost half the subjects had a meaningful improvement in symptoms. In pediatric OCD patients, the glutamate caudate concentration was abnormally increased, but it decreased after paroxetine treatment (3). Memantine, an N-methyl-D-aspartate receptor antagonist, appears to reduce glutamate excitability and improve impulsive behaviors, suggesting it may help individuals with CB. in 2012, patients with moderate to severe OCD taking memantine and fluoxetine were more likely to achieve remission after 8 weeks than patients taking placebo and fluoxetine. In regards to your experiences, would you agree this has anti obsessive properties, and should it be worth the risk of trying. This study provides preliminary supportive evidence for the effectiveness of memantine as a glutamatergic augmenting agent in severe OCD. However, in a recent double-blind, placebo-controlled, study, memantine was not effective in the treatment of major depressive disorder (Zarate et al., 2006). Background: Data from the fields of genetics, neuroimaging, and animal studies, along with case reports and small clinical trials, point to a role for glutamatergic dysfunction in the pathophysiology of obsessive-compulsive disorder (OCD). OCD, ASD), will be randomised into study period II. share. Brief Summary: The objective of this study was to obtain preliminary open-label data on the efficacy and tolerability of memantine, an anti-glutamatergic medication with a unique pharmacodynamic profile, in individuals with OCD and individuals with GAD. Memantine also affects NMDA receptors, but its effect is much weaker than that of ketamine. 1304, No. potentially impact OCD severity in a time-dependent manner). In the study by Feusner et al. Thus, attenuating glutamatergic hyperactivity might be beneficial in OCD. I'm now on Venvanse and Memantine, and 50-70% covered with this combo. The investigators hypothesized that memantine is an effective augmenting agent to standard intensive residential treatment of severe OCD. We report a therapeutic effect of add-on memantine, an N-methyl-d-aspartic acid glutamatergic receptor antagonist, in treatment-resistant OCD. Poyurovsky M, Koran LM: Obsessive-compulsive disorder (OCD) with schizotypy vs schizophrenia with OCD: diagnostic dilemmas and therapeutic implications. Response was defined as a 25% or greater reduction in the Y-BOCS score at study end and a Clinical Global Impression-Improvement scale rating of "much" or "very much" improved. The objective of this study was to compare the efficacy and safety of memantine in OCD and GAD, and to probe relative effects on OCD and anxiety symptoms. Another study suggests that OCD patients can benefit from three weeks of electro-acupuncture, but these studies were not randomized; more research is needed. Subsequent adequate trials with paroxetine and sertraline were ineffective. [Efficacy of antipsychotic augmentation therapy in treatment-resistant obsessive-compulsive disorder: a meta-analysis of double-blind, randomised, placebo-controlled trials]. 231, No. Rosenberg DR, MacMaster FP, Keshavan MS, Fitzgerald KD, Stewart CM, Moore GJ: Decrease in caudate glutamatergic concentrations in pediatric obsessive-compulsive disorder patients taking paroxetine. 1, 5 April 2013 | Philosophical Transactions of the Royal Society B: Biological Sciences, Vol. Responders had significantly lower baseline Y-BOCS scores (2-tailed t tests, P < 0.05, t = 2.2) and had failed fewer SRIs (P